Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.

Alphabet gains on AI-driven cloud, while YouTube and Google One push subscriptions past 270M despite litigation and cloud ...

Zacks spotlights Alphabet, Bank of America, Roche, Village Super Market and Aware in fresh analyst reports highlighting key ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

This patient perspectives interview features Stacy Courtnay, who shared her experience managing rheumatoid arthritis during pregnancy.

Actemra was already being used in patients with COVID-19 in the US under compassionate use regulations, allowing Roche to record a spike in sales of the drug, which climbed 30% to around $688 ...

Medical Digital Intelligence or MDI (medicaldigitalintelligence-b-2.com) is the latest scam cloaked in healthcare branding, ...